Takeda's Oveporexton Shows Positive Phase 3 Results for Narcolepsy Type 1

Takeda announced positive topline results from two pivotal Phase 3 studies (FirstLight and RadiantLight) of oveporexton (TAK-861) in narcolepsy type 1...